Industry Research Reports
Home > Reports > Medical Devices & Consumables > Global Congestive Heart Failure (CHF) Treatment Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Congestive Heart Failure (CHF) Treatment Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Congestive Heart Failure (CHF) Treatment Devices Market Size(US$)
CAGR 2025-2031
3.1%
Market Size,2031
USD 6,730
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 5,603 million
Market Forecast in 2031(Value)
US$ 6,730 million
CAGR
3.1%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Congestive Heart Failure (CHF) Treatment Devices market is projected to grow from US$ 5451 million in 2024 to US$ 6730 million by 2031, at a CAGR of 3.1% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Congestive Heart Failure (CHF) Treatment Devices market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
- Abiomed
- Berlin Heart GmbH
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- HeartWare International
- Jarvik Heart
- LivaNova PLC
- Medtronic
- ReliantHeart
- Abbott
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Cardiac Resynchronization Therapy (CRT)
- Implantable Cardioverter Defibrillators (ICDs)
Segment by Application
- Left Ventricular Assist Device (LVAD)
- Right Ventricular Assist Device (RVAD)
- Biventricular Assist Device (BIVAD)
Chapter Outline
Chapter 1: Defines the Congestive Heart Failure (CHF) Treatment Devices study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
Table of Contents
1 Study Coverage
1.1 Introduction to Congestive Heart Failure (CHF) Treatment Devices: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Congestive Heart Failure (CHF) Treatment Devices Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Cardiac Resynchronization Therapy (CRT)
1.2.3 Implantable Cardioverter Defibrillators (ICDs)
1.3 Market Segmentation by Application
1.3.1 Global Congestive Heart Failure (CHF) Treatment Devices Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Left Ventricular Assist Device (LVAD)
1.3.3 Right Ventricular Assist Device (RVAD)
1.3.4 Biventricular Assist Device (BIVAD)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Congestive Heart Failure (CHF) Treatment Devices Revenue Estimates and Forecasts 2020-2031
2.2 Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Congestive Heart Failure (CHF) Treatment Devices Sales Estimates and Forecasts 2020-2031
2.4 Global Congestive Heart Failure (CHF) Treatment Devices Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Congestive Heart Failure (CHF) Treatment Devices Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Congestive Heart Failure (CHF) Treatment Devices Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Cardiac Resynchronization Therapy (CRT) Market Size by Manufacturers
3.5.2 Implantable Cardioverter Defibrillators (ICDs) Market Size by Manufacturers
3.6 Global Congestive Heart Failure (CHF) Treatment Devices Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Congestive Heart Failure (CHF) Treatment Devices Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Congestive Heart Failure (CHF) Treatment Devices Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Congestive Heart Failure (CHF) Treatment Devices Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Type (2020-2031)
6.4 North America Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Congestive Heart Failure (CHF) Treatment Devices Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Type (2020-2031)
7.4 Europe Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Congestive Heart Failure (CHF) Treatment Devices Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Type (2020-2031)
9.4 Central and South America Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Congestive Heart Failure (CHF) Treatment Devices Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Abiomed
11.1.1 Abiomed Corporation Information
11.1.2 Abiomed Business Overview
11.1.3 Abiomed Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.1.4 Abiomed Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Abiomed Congestive Heart Failure (CHF) Treatment Devices Sales by Product in 2024
11.1.6 Abiomed Congestive Heart Failure (CHF) Treatment Devices Sales by Application in 2024
11.1.7 Abiomed Congestive Heart Failure (CHF) Treatment Devices Sales by Geographic Area in 2024
11.1.8 Abiomed Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
11.1.9 Abiomed Recent Developments
11.2 Berlin Heart GmbH
11.2.1 Berlin Heart GmbH Corporation Information
11.2.2 Berlin Heart GmbH Business Overview
11.2.3 Berlin Heart GmbH Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.2.4 Berlin Heart GmbH Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Berlin Heart GmbH Congestive Heart Failure (CHF) Treatment Devices Sales by Product in 2024
11.2.6 Berlin Heart GmbH Congestive Heart Failure (CHF) Treatment Devices Sales by Application in 2024
11.2.7 Berlin Heart GmbH Congestive Heart Failure (CHF) Treatment Devices Sales by Geographic Area in 2024
11.2.8 Berlin Heart GmbH Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
11.2.9 Berlin Heart GmbH Recent Developments
11.3 Biotronik SE & Co. KG
11.3.1 Biotronik SE & Co. KG Corporation Information
11.3.2 Biotronik SE & Co. KG Business Overview
11.3.3 Biotronik SE & Co. KG Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.3.4 Biotronik SE & Co. KG Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Biotronik SE & Co. KG Congestive Heart Failure (CHF) Treatment Devices Sales by Product in 2024
11.3.6 Biotronik SE & Co. KG Congestive Heart Failure (CHF) Treatment Devices Sales by Application in 2024
11.3.7 Biotronik SE & Co. KG Congestive Heart Failure (CHF) Treatment Devices Sales by Geographic Area in 2024
11.3.8 Biotronik SE & Co. KG Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
11.3.9 Biotronik SE & Co. KG Recent Developments
11.4 Boston Scientific Corporation
11.4.1 Boston Scientific Corporation Corporation Information
11.4.2 Boston Scientific Corporation Business Overview
11.4.3 Boston Scientific Corporation Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.4.4 Boston Scientific Corporation Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Boston Scientific Corporation Congestive Heart Failure (CHF) Treatment Devices Sales by Product in 2024
11.4.6 Boston Scientific Corporation Congestive Heart Failure (CHF) Treatment Devices Sales by Application in 2024
11.4.7 Boston Scientific Corporation Congestive Heart Failure (CHF) Treatment Devices Sales by Geographic Area in 2024
11.4.8 Boston Scientific Corporation Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
11.4.9 Boston Scientific Corporation Recent Developments
11.5 HeartWare International
11.5.1 HeartWare International Corporation Information
11.5.2 HeartWare International Business Overview
11.5.3 HeartWare International Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.5.4 HeartWare International Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 HeartWare International Congestive Heart Failure (CHF) Treatment Devices Sales by Product in 2024
11.5.6 HeartWare International Congestive Heart Failure (CHF) Treatment Devices Sales by Application in 2024
11.5.7 HeartWare International Congestive Heart Failure (CHF) Treatment Devices Sales by Geographic Area in 2024
11.5.8 HeartWare International Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
11.5.9 HeartWare International Recent Developments
11.6 Jarvik Heart
11.6.1 Jarvik Heart Corporation Information
11.6.2 Jarvik Heart Business Overview
11.6.3 Jarvik Heart Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.6.4 Jarvik Heart Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Jarvik Heart Recent Developments
11.7 LivaNova PLC
11.7.1 LivaNova PLC Corporation Information
11.7.2 LivaNova PLC Business Overview
11.7.3 LivaNova PLC Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.7.4 LivaNova PLC Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 LivaNova PLC Recent Developments
11.8 Medtronic
11.8.1 Medtronic Corporation Information
11.8.2 Medtronic Business Overview
11.8.3 Medtronic Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.8.4 Medtronic Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Medtronic Recent Developments
11.9 ReliantHeart
11.9.1 ReliantHeart Corporation Information
11.9.2 ReliantHeart Business Overview
11.9.3 ReliantHeart Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.9.4 ReliantHeart Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 ReliantHeart Recent Developments
11.10 Abbott
11.10.1 Abbott Corporation Information
11.10.2 Abbott Business Overview
11.10.3 Abbott Congestive Heart Failure (CHF) Treatment Devices Product Models, Descriptions and Specifications
11.10.4 Abbott Congestive Heart Failure (CHF) Treatment Devices Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Abbott Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Congestive Heart Failure (CHF) Treatment Devices Industry Chain
12.2 Congestive Heart Failure (CHF) Treatment Devices Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Congestive Heart Failure (CHF) Treatment Devices Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Congestive Heart Failure (CHF) Treatment Devices Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Congestive Heart Failure (CHF) Treatment Devices Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Congestive Heart Failure (CHF) Treatment Devices Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
Table of Figures
List of Tables
Table 1. Global Congestive Heart Failure (CHF) Treatment Devices Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Congestive Heart Failure (CHF) Treatment Devices Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Congestive Heart Failure (CHF) Treatment Devices Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Congestive Heart Failure (CHF) Treatment Devices Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Congestive Heart Failure (CHF) Treatment Devices Sales by Region (2020-2025) & (K Units)
Table 8. Global Congestive Heart Failure (CHF) Treatment Devices Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Congestive Heart Failure (CHF) Treatment Devices Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Congestive Heart Failure (CHF) Treatment Devices Sales Share by Manufacturers (2020-2025)
Table 12. Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Congestive Heart Failure (CHF) Treatment Devices Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Congestive Heart Failure (CHF) Treatment Devices by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Congestive Heart Failure (CHF) Treatment Devices as of 2024)
Table 16. Global Congestive Heart Failure (CHF) Treatment Devices Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Congestive Heart Failure (CHF) Treatment Devices Average Selling Price (ASP) by Manufacturers (2020-2025) & (USD/Unit)
Table 18. Key Manufacturers Congestive Heart Failure (CHF) Treatment Devices Manufacturing Base and Headquarters
Table 19. Global Congestive Heart Failure (CHF) Treatment Devices Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Congestive Heart Failure (CHF) Treatment Devices Sales by Type (2020-2025) & (K Units)
Table 23. Global Congestive Heart Failure (CHF) Treatment Devices Sales by Type (2026-2031) & (K Units)
Table 24. Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Congestive Heart Failure (CHF) Treatment Devices ASP by Type (2020-2031) & (USD/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Congestive Heart Failure (CHF) Treatment Devices Sales by Application (2020-2025) & (K Units)
Table 29. Global Congestive Heart Failure (CHF) Treatment Devices Sales by Application (2026-2031) & (K Units)
Table 30. Congestive Heart Failure (CHF) Treatment Devices High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Congestive Heart Failure (CHF) Treatment Devices Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Congestive Heart Failure (CHF) Treatment Devices ASP by Application (2020-2031) & (USD/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Congestive Heart Failure (CHF) Treatment Devices Growth Accelerators and Market Barriers
Table 37. North America Congestive Heart Failure (CHF) Treatment Devices Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Congestive Heart Failure (CHF) Treatment Devices Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Congestive Heart Failure (CHF) Treatment Devices Growth Accelerators and Market Barriers
Table 40. Europe Congestive Heart Failure (CHF) Treatment Devices Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Congestive Heart Failure (CHF) Treatment Devices Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Growth Accelerators and Market Barriers
Table 45. Southeast Asia Congestive Heart Failure (CHF) Treatment Devices Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Congestive Heart Failure (CHF) Treatment Devices Investment Opportunities and Key Challenges
Table 47. Central and South America Congestive Heart Failure (CHF) Treatment Devices Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Abiomed Corporation Information
Table 51. Abiomed Description and Major Businesses
Table 52. Abiomed Product Models, Descriptions and Specifications
Table 53. Abiomed Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 54. Abiomed Sales Value Proportion by Product in 2024
Table 55. Abiomed Sales Value Proportion by Application in 2024
Table 56. Abiomed Sales Value Proportion by Geographic Area in 2024
Table 57. Abiomed Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
Table 58. Abiomed Recent Developments
Table 59. Berlin Heart GmbH Corporation Information
Table 60. Berlin Heart GmbH Description and Major Businesses
Table 61. Berlin Heart GmbH Product Models, Descriptions and Specifications
Table 62. Berlin Heart GmbH Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 63. Berlin Heart GmbH Sales Value Proportion by Product in 2024
Table 64. Berlin Heart GmbH Sales Value Proportion by Application in 2024
Table 65. Berlin Heart GmbH Sales Value Proportion by Geographic Area in 2024
Table 66. Berlin Heart GmbH Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
Table 67. Berlin Heart GmbH Recent Developments
Table 68. Biotronik SE & Co. KG Corporation Information
Table 69. Biotronik SE & Co. KG Description and Major Businesses
Table 70. Biotronik SE & Co. KG Product Models, Descriptions and Specifications
Table 71. Biotronik SE & Co. KG Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 72. Biotronik SE & Co. KG Sales Value Proportion by Product in 2024
Table 73. Biotronik SE & Co. KG Sales Value Proportion by Application in 2024
Table 74. Biotronik SE & Co. KG Sales Value Proportion by Geographic Area in 2024
Table 75. Biotronik SE & Co. KG Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
Table 76. Biotronik SE & Co. KG Recent Developments
Table 77. Boston Scientific Corporation Corporation Information
Table 78. Boston Scientific Corporation Description and Major Businesses
Table 79. Boston Scientific Corporation Product Models, Descriptions and Specifications
Table 80. Boston Scientific Corporation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 81. Boston Scientific Corporation Sales Value Proportion by Product in 2024
Table 82. Boston Scientific Corporation Sales Value Proportion by Application in 2024
Table 83. Boston Scientific Corporation Sales Value Proportion by Geographic Area in 2024
Table 84. Boston Scientific Corporation Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
Table 85. Boston Scientific Corporation Recent Developments
Table 86. HeartWare International Corporation Information
Table 87. HeartWare International Description and Major Businesses
Table 88. HeartWare International Product Models, Descriptions and Specifications
Table 89. HeartWare International Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 90. HeartWare International Sales Value Proportion by Product in 2024
Table 91. HeartWare International Sales Value Proportion by Application in 2024
Table 92. HeartWare International Sales Value Proportion by Geographic Area in 2024
Table 93. HeartWare International Congestive Heart Failure (CHF) Treatment Devices SWOT Analysis
Table 94. HeartWare International Recent Developments
Table 95. Jarvik Heart Corporation Information
Table 96. Jarvik Heart Description and Major Businesses
Table 97. Jarvik Heart Product Models, Descriptions and Specifications
Table 98. Jarvik Heart Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 99. Jarvik Heart Recent Developments
Table 100. LivaNova PLC Corporation Information
Table 101. LivaNova PLC Description and Major Businesses
Table 102. LivaNova PLC Product Models, Descriptions and Specifications
Table 103. LivaNova PLC Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 104. LivaNova PLC Recent Developments
Table 105. Medtronic Corporation Information
Table 106. Medtronic Description and Major Businesses
Table 107. Medtronic Product Models, Descriptions and Specifications
Table 108. Medtronic Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 109. Medtronic Recent Developments
Table 110. ReliantHeart Corporation Information
Table 111. ReliantHeart Description and Major Businesses
Table 112. ReliantHeart Product Models, Descriptions and Specifications
Table 113. ReliantHeart Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 114. ReliantHeart Recent Developments
Table 115. Abbott Corporation Information
Table 116. Abbott Description and Major Businesses
Table 117. Abbott Product Models, Descriptions and Specifications
Table 118. Abbott Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 119. Abbott Recent Developments
Table 120. Key Raw Materials Distribution
Table 121. Raw Materials Key Suppliers
Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 123. Milestones in Production Technology Evolution
Table 124. Distributors List
Table 125. Market Trends and Market Evolution
Table 126. Market Drivers and Opportunities
Table 127. Market Challenges, Risks, and Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Congestive Heart Failure (CHF) Treatment Devices Product Picture
Figure 2. Global Congestive Heart Failure (CHF) Treatment Devices Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Cardiac Resynchronization Therapy (CRT) Product Picture
Figure 4. Implantable Cardioverter Defibrillators (ICDs) Product Picture
Figure 5. Global Congestive Heart Failure (CHF) Treatment Devices Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Left Ventricular Assist Device (LVAD)
Figure 7. Right Ventricular Assist Device (RVAD)
Figure 8. Biventricular Assist Device (BIVAD)
Figure 9. Congestive Heart Failure (CHF) Treatment Devices Report Years Considered
Figure 10. Global Congestive Heart Failure (CHF) Treatment Devices Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 12. Global Congestive Heart Failure (CHF) Treatment Devices Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Congestive Heart Failure (CHF) Treatment Devices Revenue Market Share by Region (2020-2031)
Figure 14. Global Congestive Heart Failure (CHF) Treatment Devices Sales (2020-2031) & (K Units)
Figure 15. Global Congestive Heart Failure (CHF) Treatment Devices Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global Congestive Heart Failure (CHF) Treatment Devices Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Congestive Heart Failure (CHF) Treatment Devices Sales Volume Market Share in 2024
Figure 18. Global Congestive Heart Failure (CHF) Treatment Devices Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Cardiac Resynchronization Therapy (CRT) Revenue Market Share by Manufacturer in 2024
Figure 21. Implantable Cardioverter Defibrillators (ICDs) Revenue Market Share by Manufacturer in 2024
Figure 22. Global Congestive Heart Failure (CHF) Treatment Devices Sales Market Share by Type (2020-2031)
Figure 23. Global Congestive Heart Failure (CHF) Treatment Devices Revenue Market Share by Type (2020-2031)
Figure 24. Global Congestive Heart Failure (CHF) Treatment Devices Sales Market Share by Application (2020-2031)
Figure 25. Global Congestive Heart Failure (CHF) Treatment Devices Revenue Market Share by Application (2020-2031)
Figure 26. North America Congestive Heart Failure (CHF) Treatment Devices Sales YoY (2020-2031) & (K Units)
Figure 27. North America Congestive Heart Failure (CHF) Treatment Devices Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) in 2024
Figure 29. North America Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Congestive Heart Failure (CHF) Treatment Devices Sales YoY (2020-2031) & (K Units)
Figure 37. Europe Congestive Heart Failure (CHF) Treatment Devices Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) in 2024
Figure 39. Europe Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 44. France Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 59. India Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Congestive Heart Failure (CHF) Treatment Devices Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America Congestive Heart Failure (CHF) Treatment Devices Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Congestive Heart Failure (CHF) Treatment Devices Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa Congestive Heart Failure (CHF) Treatment Devices Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Congestive Heart Failure (CHF) Treatment Devices Revenue (2020-2025) & (US$ Million)
Figure 80. Congestive Heart Failure (CHF) Treatment Devices Industry Chain Mapping
Figure 81. Regional Congestive Heart Failure (CHF) Treatment Devices Manufacturing Base Distribution (%)
Figure 82. Global Congestive Heart Failure (CHF) Treatment Devices Production Market Share by Region (2020-2031)
Figure 83. Congestive Heart Failure (CHF) Treatment Devices Production Process
Figure 84. Regional Congestive Heart Failure (CHF) Treatment Devices Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Related Reports
Global Congestive Heart Failure (CHF) Treatment Devices Market Research Report 2024
Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
Published Date: 2024-01-16
Pages: 94
USD 2900.00
(Single User License)
Congestive Heart Failure (CHF) Treatment Devices - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
Published Date: 2024-01-24
Pages: 123
USD 3950.00
(Single User License)
Global Congestive Heart Failure (CHF) Treatment Devices Market Insights, Forecast to 2030
Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
Published Date: 2024-04-12
Pages: 107
USD 4900.00
(Single User License)
Global Congestive Heart Failure (CHF) Treatment Devices Market Research Report 2025
The global market for Congestive Heart Failure (CHF) Treatment Devices was valued at US$ 5451 million in the year 2024 and is projected to reach a revised size of US$ 6730 million by 2031, growing at a CAGR of 3.1% during the forecast period.
Published Date: 2025-02-25
Pages: 86
USD 2900.00
(Single User License)
Congestive Heart Failure (CHF) Treatment Devices- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Congestive Heart Failure (CHF) Treatment Devices was estimated to be worth US$ 5451 million in 2024 and is forecast to a readjusted size of US$ 6730 million by 2031 with a CAGR of 3.1% during the forecast period 2025-2031.
Published Date: 2025-02-25
Pages: 110
USD 3950.00
(Single User License)
Global Congestive Heart Failure (CHF) Treatment Devices Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Congestive Heart Failure (CHF) Treatment Devices market size was US$ 5451 million in 2024 and is forecast to a readjusted size of US$ 6730 million by 2031 with a CAGR of 3.1% during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 78
USD 4250.00
(Single User License)
Global Congestive Heart Failure (CHF) Treatment Devices Market Research Report 2026
The global Congestive Heart Failure (CHF) Treatment Devices market was valued at US$ 5603 million in 2025 and is anticipated to reach US$ 6918 million by 2032, at a CAGR of 3.1% from 2026 to 2032.
Published Date: 2026-04-27
Pages: 115
USD 2900.00
(Single User License)
Congestive Heart Failure (CHF) Treatment Devices- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Congestive Heart Failure (CHF) Treatment Devices was estimated to be worth US$ 5603 million in 2025 and is projected to reach US$ 6918 million, growing at a CAGR of 3.1% from 2026 to 2032.
Published Date: 2026-07-14
Pages: 135
USD 3950.00
(Single User License)
Global Congestive Heart Failure (CHF) Treatment Devices Market Research Report 2024
Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
Published: 2024-01-16
Pages: 94
USD 2900.00 (Single User License)Congestive Heart Failure (CHF) Treatment Devices - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
Published: 2024-01-24
Pages: 123
USD 3950.00 (Single User License)Global Congestive Heart Failure (CHF) Treatment Devices Market Insights, Forecast to 2030
Congestive heart failure (CHF) is a physiological condition that has an adverse impact on the pumping efficiency of the cardiac muscles. It characterizes the accumulation of fluid around the heart leading to inefficient pumping. The onset of CHF is marked by the failure of the ventricles to pump sufficient volume of blood to the body organs. This eventually leads to deposition of fluid in the lungs, abdomen, liver, and lower body. CHF is treated by a number of devices that maintain heart rhythm, such as pacemakers, cardiac resynchronization therapy (CRT), implantable cardioverter defibrillators (ICDs), and ventricular assist devices (VADs).
Published: 2024-04-12
Pages: 107
USD 4900.00 (Single User License)Global Congestive Heart Failure (CHF) Treatment Devices Market Research Report 2025
The global market for Congestive Heart Failure (CHF) Treatment Devices was valued at US$ 5451 million in the year 2024 and is projected to reach a revised size of US$ 6730 million by 2031, growing at a CAGR of 3.1% during the forecast period.
Published: 2025-02-25
Pages: 86
USD 2900.00 (Single User License)Congestive Heart Failure (CHF) Treatment Devices- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Congestive Heart Failure (CHF) Treatment Devices was estimated to be worth US$ 5451 million in 2024 and is forecast to a readjusted size of US$ 6730 million by 2031 with a CAGR of 3.1% during the forecast period 2025-2031.
Published: 2025-02-25
Pages: 110
USD 3950.00 (Single User License)Global Congestive Heart Failure (CHF) Treatment Devices Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Congestive Heart Failure (CHF) Treatment Devices market size was US$ 5451 million in 2024 and is forecast to a readjusted size of US$ 6730 million by 2031 with a CAGR of 3.1% during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 78
USD 4250.00 (Single User License)Global Congestive Heart Failure (CHF) Treatment Devices Market Research Report 2026
The global Congestive Heart Failure (CHF) Treatment Devices market was valued at US$ 5603 million in 2025 and is anticipated to reach US$ 6918 million by 2032, at a CAGR of 3.1% from 2026 to 2032.
Published: 2026-04-27
Pages: 115
USD 2900.00 (Single User License)Congestive Heart Failure (CHF) Treatment Devices- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Congestive Heart Failure (CHF) Treatment Devices was estimated to be worth US$ 5603 million in 2025 and is projected to reach US$ 6918 million, growing at a CAGR of 3.1% from 2026 to 2032.
Published: 2026-07-14
Pages: 135
USD 3950.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
Market Segmentation
Why This Report?
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
Interest In This Report?
Get A Free Sample
Pre-Order Enquiry
OR
Need a Tailored Report?
Customize this report to your needs.
Customize This Report
Fact Checked
Cite this Research